

Shrujal S Baxi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6420388/publications.pdf>

Version: 2024-02-01

57
papers

6,621
citations

236612

25
h-index

155451

55
g-index

57
all docs

57
docs citations

57
times ranked

13021
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
2	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
3	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 360, k793.	2.4	438
4	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239
5	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	3.4	191
6	Causes of death in long-term survivors of head and neck cancer. <i>Cancer</i> , 2014, 120, 1507-1513.	2.0	175
7	Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	1.8	165
8	Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. <i>Cancer</i> , 2016, 122, 1523-1532.	2.0	128
9	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 9-17.	0.4	121
10	Synchronous cancers in patients with head and neck cancer. <i>Cancer</i> , 2013, 119, 1832-1837.	2.0	98
11	Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1140-1163.	2.3	81
12	Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). <i>Anticancer Research</i> , 2011, 31, 249-53.	0.5	66
13	Solid Tumor Second Primary Neoplasms: Who Is at Risk, What Can We Do?. <i>Seminars in Oncology</i> , 2013, 40, 676-689.	0.8	60
14	Survivorship care plans: Is there buy-in from community oncology providers?. <i>Cancer</i> , 2014, 120, 722-730.	2.0	59
15	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. <i>Cancer</i> , 2017, 123, 4114-4121.	2.0	59
16	Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis. <i>Cancer</i> , 2015, 121, 2083-2089.	2.0	54
17	Sharing a diagnosis of HPV-related head and neck cancer: The emotions, the confusion, and what patients want to know. <i>Head and Neck</i> , 2013, 35, 1534-1541.	0.9	52
18	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 564-570.	0.4	51

#	ARTICLE	IF	CITATIONS
19	Patient Reflections on Decision Making for Laryngeal Cancer Treatment. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 299-304.	1.1	47
20	Treatment complications and survival in advanced laryngeal cancer: A population-based analysis. <i>Laryngoscope</i> , 2014, 124, 2707-2713.	1.1	46
21	Ten Years of Progress in Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 806-810.	2.3	44
22	Overuse of Health Care Services in the Management of Cancer. <i>Medical Care</i> , 2017, 55, 723-733.	1.1	39
23	Phase II trial of bevacizumab+cetuximab+cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E566-70.	0.9	35
24	Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 62, 147-148.	0.8	32
25	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. <i>Thyroid</i> , 2022, 32, 273-282.	2.4	30
26	Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. <i>Head and Neck</i> , 2016, 38, E165-71.	0.9	26
27	Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information. <i>Journal of Oncology Practice</i> , 2014, 10, e277-e282.	2.5	25
28	A review of weight loss and sarcopenia in patients with head and neck cancer treated with chemoradiation. <i>Cancers of the Head & Neck</i> , 2016, 1, 9.	6.2	25
29	State-of-the-art Issues in Hodgkin's Lymphoma Survivorship. <i>Current Oncology Reports</i> , 2010, 12, 366-373.	1.8	24
30	Moving survivorship care plans forward: focus on care coordination. <i>Cancer Medicine</i> , 2016, 5, 1717-1722.	1.3	23
31	Quality of Cancer Surveillance Clinical Practice Guidelines. <i>JAMA Internal Medicine</i> , 2017, 177, 701.	2.6	20
32	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Cancer</i> , 2017, 123, 1345-1353.	2.0	20
33	Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1209.	3.8	20
34	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 4.	6.2	19
35	The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. <i>Journal of Psychosocial Oncology</i> , 2021, 39, 285-293.	0.6	18
36	Association of Number of Dissected Lymph Nodes With Survival in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma Patients Undergoing Primary Surgery. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1049.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Incorporating Multiple Perspectives Into the Development of an Electronic Survivorship Platform for Head and Neck Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-15.	1.0	13
38	First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. <i>Future Oncology</i> , 2020, 16, 4341-4345.	1.1	10
39	Value Considerations in the Treatment of Head and Neck Cancer: Radiation, Chemotherapy, and Supportive Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e296-e303.	1.8	9
40	Breast Imaging Fellowships in the United States: Who, What, and Where?. <i>American Journal of Roentgenology</i> , 2009, 192, 403-407.	1.0	8
41	The Future of Mammography: Radiology Residents' Experiences, Attitudes, and Opinions. <i>American Journal of Roentgenology</i> , 2010, 194, 1680-1686.	1.0	8
42	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. <i>Journal of Oncology Practice</i> , 2018, 14, 72-76.	2.5	8
43	Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma. <i>Future Oncology</i> , 2021, 17, 3037-3050.	1.1	7
44	Reply to B. O'Sullivan et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1710-1710.	0.8	6
45	Long-term quality of life in older patients with HPV-related oropharyngeal cancer. <i>Head and Neck</i> , 2018, 40, 2321-2328.	0.9	6
46	Using electronic health record data to identify comparator populations for comparative effectiveness research. <i>Journal of Medical Economics</i> , 2020, 23, 1618-1622.	1.0	6
47	Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e1753-e1762.	1.9	6
48	Hemorrhagic Pseudoaneurysm in a Patient Receiving Aflibercept for Metastatic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 552-555.	2.4	4
49	Evaluating the Potential Role of PET/CT in the Posttreatment Surveillance of Head and Neck Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 252-254.	2.3	4
50	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. <i>Cancer</i> , 2019, 125, 2984-2990.	2.0	4
51	Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer. <i>Value in Health</i> , 2022, 25, 230-237.	0.1	3
52	Letting the GENIE Out of Its Bottle: Examining the Potential of Real-World Clinicogenomic Data. <i>Cancer Discovery</i> , 2020, 10, 490-491.	7.7	2
53	Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. <i>European Endocrinology</i> , 2017, 13, 26.	0.8	2
54	Acute Limbic Encephalitis: Diagnostic and Management Implications. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 166-169.	1.3	1

#	ARTICLE	IF	CITATIONS
55	OP520 Evaluating Long-Term Survival From Clinical Trials: Does Real-World Evidence Change the Paradigm?. International Journal of Technology Assessment in Health Care, 2020, 36, 12-12.	0.2	1
56	Consider Quality of Life to Improve Quality of Cancer Guidelinesâ€”Reply. JAMA Internal Medicine, 2017, 177, 1538.	2.6	0
57	Automating Treatment Summary Development Using Electronic Billing Information: A Pilot Study of Survivors of Head and Neck Cancer. Journal of Oncology Practice, 2019, 15, e84-e90.	2.5	0